In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...

Despite the long holiday weekend, news in biopharma never slows down. | This week on "The Top Line," we break down ...

Hey, AbbVie, what do you say? The Cubs are gonna strike out cancer today. | A new partnership between the Chicago-based ...

Astellas is banging the drum for patient advocacy organizations (PAOs) again. | Astellas is banging the drum for patient ...

In the wake of sweeping cuts at the FDA’s Office of Prescription Drug Promotion (OPDP), Sen. | In the wake of sweeping cuts ...